← Back to patent-cliff list
QLS-111-FDC
Tier C — Watch / tradeQLS-111-FDC
Qlaris Bio Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：KATP channels
Indications (approved)：Ocular hypertension, Open-angle glaucoma
Regional status
US
Phase III
2026-03-18
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of QLS-111-FDC?
Approved indications include: Ocular hypertension, Open-angle glaucoma.
When does the QLS-111-FDC patent expire?
No public expiry year is available for QLS-111-FDC yet; this page updates once verified.
How do I get a quote for QLS-111-FDC intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29